-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
CMMB:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 1Change
-0.02 (-2.39)%Market Cap
USD 0.01BVolume
0.05MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 1Change
-0.02 (-2.39)%Market Cap
USD 0.01BVolume
0.05MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
N/A |
USD 122.24B |
REGN | Regeneron Pharmaceuticals Inc |
N/A |
USD 115.08B |
MRNA | Moderna Inc |
N/A |
USD 51.07B |
ALNY | Alnylam Pharmaceuticals Inc |
N/A |
USD 28.20B |
ARGX | argenx NV ADR |
N/A |
USD 26.78B |
BNTX | BioNTech SE |
N/A |
USD 20.40B |
BGNE | BeiGene Ltd |
N/A |
USD 17.50B |
GMAB | Genmab AS |
N/A |
USD 16.65B |
BMRN | Biomarin Pharmaceutical Inc |
N/A |
USD 15.98B |
RPRX | Royalty Pharma Plc |
N/A |
USD 15.90B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
ECON | Columbia Emerging Markets.. | 4.76 % | 0.61 % |
N/A |
USD 0.06B |
BLES | Inspire Global Hope ETF | 0.00 % | 0.62 % |
N/A |
USD 0.11B |
WWJD | Inspire International ESG.. | 0.00 % | 0.00 % |
N/A |
USD 0.29B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 96.08% | 92% | A | 96% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 96.08% | 92% | A | 96% | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | -18.08% | 59% | D- | 38% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -18.08% | 59% | D- | 37% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -46.22% | 7% | C- | 3% | F | ||
Dividend Return | -46.22% | 7% | C- | 3% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 32.75% | 79% | B- | 57% | F | ||
Risk Adjusted Return | -141.14% | 2% | F | 1% | F | ||
Market Capitalization | 0.01B | 17% | F | 13% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector